Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia

被引：0
作者：
Jeevan Kumar
Afaq Ahmad Khan
Amrita Saraf
Manorama Bhargava
机构：
[1] Sir Ganga Ram Hospital,Department of Hematology
来源：
Indian Journal of Hematology and Blood Transfusion | 2014年 / 30卷
关键词：
BCP-ALL; CD20 antigen; Rituximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
CD20 is a B cell differentiation antigen with variable expression in B cell precursor acute lymphoblastic leukemia (BCP-ALL). The significance of CD20 expression has been evaluated in BCP-ALL with conflicting results. There is paucity of data regarding CD 20 expression in BCP-ALL in Indian patients. We retrospectively analyzed 100 patients of BCP-ALL for CD20 expression. CD20 positivity was defined as expression of CD20 to be more than or equal to 20 % in the blast population. 62 % patients expressed CD20 while 38 % patients were negative for CD20. The positivity ranged from negative to dim (35.5 % patients), moderately bright (19.3 % patients) to bright (45.2 % patients). Additional prospective studies are needed to determine the optimal use of rituximab in treatment of CD20-positive BCP-ALL.
引用
收藏
页码：16 / 18
页数：2
相关论文
共 43 条
  • [1] Jeha S(2006)Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia Blood 108 3302-3304
  • [2] Behm F(1997)Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study Blood 89 3960-3966
  • [3] Pei D(2004)Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects Ann Hematol 83 201-205
  • [4] Borowitz MJ(2008)CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy Blood 112 3982-3988
  • [5] Shuster J(2010)Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia Haematologica 95 324-328
  • [6] Carroll AJ(2004)Monoclonal antibodies as therapeutic agents for cancer Lancet Oncol 5 292-302
  • [7] Gökbuget N(2006)Chemoimmunotherapy with hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia Cancer 106 1569-1580
  • [8] Hoelzer D(2006)Rituximab plus chemotherapy in children with relapsed or refractory CD20 B-cell precursor acute lymphoblastic leukemia Haematologica 91 272-273
  • [9] Dworzak MN(2007)Remission induction with single agent Rituximab in a child with multiply relapsed precursor-B ALL Br J Haemotol 139 344-345
  • [10] Schumich A(undefined)undefined undefined undefined undefined-undefined
12345